748410
Last Update Posted: 2020-10-30
Recruiting has ended
All Genders accepted | Under |
3 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Study to Evaluate the Pharmacodynamics of SB-656933 in Patients With Ulcerative Colitis
This study will involve the use of a new compound, SB-656933. Accumulation of inflammatory white blood cells (mostly polymorphonuclear neutrophils)in the gut (colon) may be contributing to the pathology of ulcerative colitis. It has been shown that SB-656933 reduces polymorphonuclear neutrophils (PMN) accumulation in pre-clinical models of colitis. 99m-Tc-HMPAO scintigraphy is a imaging technique which will be used in this study to observe the effect of SB656933 on the migration of PMN to inflamed tissue.
Eligibility
Relevant conditions:
Colitis, Ulcerative
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov